Successful management of adult hemophagocytic lymphohistiocytosis with an etoposide-containing regimen: Case report and literature review Etoposide for adult hemophagocytosis
Article Sidebar
Main Article Content
Abstract
Objective: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disorder characterized by a hyperimmune response. Although HLH is well described in the pediatric population, less is known about the appropriate management in adults. Despite the inclusion of etoposide in HLH society protocols, some clinicians refrain from using it due to its cytotoxicity and potential adverse effects.
Case: We report here the case of a 43-year-old male presenting with fever and pancytopenia, who was diagnosed with HLH following further evaluation. The patient immediately started the HLH-2004 initial protocol, which consisted of dexamethasone, etoposide, cyclosporine, and IVIG. Symptoms improved after 2 weeks of treatment. Subsequent bone marrow biopsy showed normal results, and the patient achieved complete remission, leading to the termination of treatment in the 12th week of the protocol. At 8 months post-treatment, the patient remained recurrence-free with normal hematological and biochemical test results.
Conclusion: This case underscores the importance of considering etoposide-containing regimens, particularly for medically fit patients.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2023-06-21
Published 2023-07-29
References
Tothova Z, Berliner N. Hemophagocytic Syndrome and Critical Illness: New Insights into Diagnosis and Management. Journal of intensive care medicine. 2015;30(7):401-12.
Hayden A, Park S, Giustini D, Lee AY, Chen LY. Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: A systematic scoping review. Blood reviews. 2016;30(6):411-20.
Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet (London, England). 2014;383(9927):1503-16.
Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatric blood & cancer. 2007;48(2):124-31.
Imashuku S. Treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis (EBV-HLH); update 2010. Journal of pediatric hematology/oncology. 2011;33(1):35-9.
Shabbir M, Lucas J, Lazarchick J, Shirai K. Secondary hemophagocytic syndrome in adults: a case series of 18 patients in a single institution and a review of literature. Hematological oncology. 2011;29(2):100-6.
Ehl S, Astigarraga I, von Bahr Greenwood T, Hines M, Horne A, Ishii E, et al. Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society. The journal of allergy and clinical immunology In practice. 2018;6(5):1508-17.
Song Y, Wang Z, Hao Z, Li L, Lu J, Kang H, et al. Requirement for etoposide in the treatment of pregnancy related hemophagocytic lymphohistiocytosis: a multicenter retrospective study. Orphanet journal of rare diseases. 2019;14(1):50.
Song Y, Wang Y, Wang Z. Requirement for etoposide in the initial treatment of Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis. British journal of haematology. 2019;186(5):717-23.
Pandey Y, Atwal D, Konda M, Bimali M, Middleton D, Yarlagadda N, et al. Hemophagocytic lymphohistiocytosis in adults. Proceedings (Baylor University Medical Center). 2020;33(3):326-30.
Bubik RJ, Barth DM, Hook C, Wolf RC, Muth JM, Mara K, et al. Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. Leukemia & lymphoma. 2020;61(7):1592-600.